Tissue Regenix Group (TRX) Share Price, News & Analysis

Company Overview

Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies in the field of bone graft substitutes and soft tissue in the United States and internationally. The company operates through dCELL, BioRinse, and GBM-V segments. It also provides dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal and human soft tissue to repair diseased or damaged body parts; and BioRinse technology, a natural bone filler solution for osteoinductivity to stimulate and regenerate native bone growth. In addition, the company offers DermaPure, a decellularised dermal allograft for reinforcement, repair, and replacement of damaged or inadequate integumental tissue and other homologous uses of human integument; and SurgiPure XD, a decellularised porcine dermal reconstructive tissue matrix for the repair of hernias and body wall defects. Further, it provides OrthoPure XT, a scaffold to replace the damaged tissue that will re-populate with the patient's own cells; ConCelltrate 100, a verified osteoinductive bone matrix; MatrixCellect 100, a demineralised bone matrix (DBM) for orthopaedic; Matrix IQ Dermis, a human-derived dermal graft, which is decellularised to remove cellular components and preserve the biological properties that promote revascularisation, repair, and augmentation of damaged tissue; and Matrix OI FlexIt, a thin pliable demineralised cortical allograft bone sheet. Additionally, the company offers DentalFix, a mineralized particulate allograft that offer osteoconductive properties of natural bone; Matrix OI 100 DBM for non-structural bone-grafting; Matrix OI Strips and Blocks, a stem cell containment human scaffold; AmnioWorks to optimise membrane defects; and sports medicine products. Tissue Regenix Group plc was incorporated in 2006 and is based in Garforth, the United Kingdom.

Key Stats

• Today's Range: 56 to 58.65
• 50-Day Range: 51.60 to 63.15
• 52-Week Range: 50 to 75
• Volume: 16,879 shs
• Average Volume: 79,076 shs
• Market Capitalization: £39.89 million
• P/E Ratio: N/A
• Dividend Yield: 4.12%
• Price Target: N/A
• Consensus Rating: N/A

TRX Stock Analysis - Frequently Asked Questions

How have TRX shares performed this year?

Tissue Regenix Group's stock was trading at GBX 52 at the beginning of 2024. Since then, TRX stock has increased by 11.5% and is now trading at GBX 58.
View the best growth stocks for 2024 here.

How were Tissue Regenix Group's earnings last quarter?

Tissue Regenix Group plc (LON:TRX) issued its earnings results on Wednesday, September, 2nd. The company reported ($0.16) earnings per share (EPS) for the quarter. Tissue Regenix Group had a negative trailing twelve-month return on equity of 3.31% and a negative net margin of 3.46%.

How do I buy shares of Tissue Regenix Group?

Shares of TRX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Tissue Regenix Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Tissue Regenix Group investors own include Lloyds Banking Group (LLOY), Argos Therapeutics (ARGSQ), FuelCell Energy (FCEL), TransEnterix (TRXDW), Swedbank AB (publ) (SWDBY), Trevena (TRVN) and Barrick Gold (ABX).

Company Calendar

• Last Earnings: 9/02/2020
• Today: 11/21/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Precious Metals
• Current Symbol: LON:TRX
• CUSIP: N/A
• CIK: N/A
• Web: www.tissueregenix.com
• Phone: +44-1904-567609
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 115.50
• P/E Growth: N/A
• Net Income: £-1,100,000.00
• Net Margins: -3.46%
• Pretax Margin: N/A
• Return on Equity: -3.31%
• Return on Assets: 0.50%

Debt

• Debt-to-Equity Ratio: 35.69
• Current Ratio: 3.74
• Quick Ratio: 2.36

Sales & Book Value

• Annual Sales: £31.80 million
• Price / Sales: 1.30
• Cash Flow: GBX 10.18 per share
• Price / Cash Flow: 5.70
• Book Value: GBX 43 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 71,230,000
• Free Float: N/A
• Market Cap: £41.31 million
• Optionable: Not Optionable
• Beta: 1.61